Title of the cohort
Turkish Alzheimer Prevalence Study
Acronym for cohort
Name of Principal Investigator
| Title | Professor |
| First name | Murat |
| Last name | Emre |
Address of institution where award is held
| Institution | Istanbul University Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit |
| Street Address | Millet Cad. Capa, Sehremini |
| City | Istanbul |
| Postcode | 34093 |
Country
Turkey
Website
www.itfnoroloji.org
Contact email
Funding source
Pharma industry
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
When studies on the above condition(s) are expected to become possible
Already possible
2a. Stated aim of the cohort
Prevalence of dementia in Istanbul
2b. Features distinguishing this cohort from other population cohorts
Door to door survey
3a. i) Number of publications that involve use of cohort to date
4
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 70 |
| To (‘until death’ if applicable): | until death |
4b. Study criteria: inclusion criteria
Only community dwelling individuals
4c. Study criteria: exclusion criteria
Subjects with severe communication (ie, aphasia or no knowledge of Turkish) and perceptual (ie, deafness or blindness) problems were excluded from the study.
5. Size of the cohort (i.e. number of participants enrolled)
1,000 – 5,000 participants
6a. Measures used to characterise participants
MMSE, neuropsychological evaluation, DSM IV, NINCDS-ADRDA, CDR
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
Demented or not
7. Study design
- Prospective cohort
- Cross sectional survey
8. Cases matched by
- Age
- Sex
- Cognitive function
9a. Does the study include a specialised subset of control participants
Yes
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-10-1999
10a. ii) Data collection end date
10a iii) Data collection for this study is
Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
11. Data collected
- Only through the study
12. System in place to enable re-contact with patients for future studies
No
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | yes | 100 |
| Database is web-based | no | |
| Database on spreadsheet | yes | 100 |
| Database is on paper | no | |
| Other (specify) |
Language used:
Turkishh and English
13b. Format and availability of data held as individual records
| Yes/No | % available | |
| Data held as individual records | no | |
| Data is web-based | no | |
| Data held on computer based records | yes | 100 |
| Data held on cards | no | |
| Other (specify) |
Language used:
Turkish and English
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Apply to PI or co-ordinator at resource
15. Data sharing policy specified as a condition of use
No policy exists
16a. Are tissues/samples/DNA available to other groups
No
16b. i) Description of available tissues/samples/DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
17. Is information on biological characteristics available to other groups
- No